-
Electronic (PDF)
-
Site License
-
Enterprisewide
Hyponatremia - Pipeline Review, H1 2012
Global Markets Direct, April 2012, Pages: 37
Hyponatremia – Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Hyponatremia - Pipeline Review, H1 2012', provides an overview of the Hyponatremia therapeutic pipeline. This report provides information on the therapeutic development for Hyponatremia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyponatremia. 'Hyponatremia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Hyponatremia.
- A review of the Hyponatremia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hyponatremia pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Hyponatremia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hyponatremia pipeline depth and focus of Hyponatremia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords
Hyponatremia Therapeutic Products under Development, Key Players in Hyponatremia Therapeutics, Hyponatremia Pipeline Overview, Hyponatremia Pipeline, Hyponatremia Pipeline Assessment
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hyponatremia Overview
Therapeutics Development
An Overview of Pipeline Products for Hyponatremia
Hyponatremia Therapeutics under Development by Companies
Hyponatremia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Hyponatremia Therapeutics – Products under Development by Companies
Hyponatremia Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Hyponatremia Therapeutics Development
Cornerstone Therapeutics Inc.
Hyponatremia – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Lixivaptan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Isotonic Parenteral Fluid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hypotonic Parenteral Fluid (Hamilton Health Sciences) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hyponatremia Therapeutics – Drug Profile Updates
Hyponatremia Therapeutics – Discontinued Products
Hyponatremia Therapeutics - Dormant Products
Hyponatremia – Product Development Milestones
Featured News & Press Releases
Mar 12, 2010: Seattle Genetics Expands Antibody-Drug Conjugate Patent Portfolio
Aug 03, 2009: The European Commission Approves Otsuka Pharmaceutical's Samsca (tolvaptan) For Hyponatremia
May 21, 2009: FDA Approves Otsuka Pharmaceutical's Samsca (tolvaptan) To Treat Patients With Clinically Significant Hypervolemic And Euvolemic Hyponatremia
Jun 25, 2008: U.S. Food And Drug Administration Advisory Committee Recommends Approval Of Tolvaptan, An Investigational Treatment For Hyponatremia
Dec 21, 2007: Otsuka Pharmaceutical's Files New Drug Application For Tolvaptan
Sep 19, 2007: ECLIPSE Data on Effects of Otsuka’s Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients’ Hemodynamics and Urine Output Featured in Heart Failure Society of America’s Late Breaking Trials
Mar 25, 2007: EVEREST Data on Short- and Long-Term Use of Otsuka’s Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACC’s Late Breaking Clinical Trials
Dec 05, 2006: New Data On Otsuka's Investigational Product for Hyponatremia Presented at American Heart Association Annual Meeting Results of the SALT-1 and SALT-2 Trials Show Tolvaptan Improves Serum Sodium Levels in Patients with Hyponatremia
Nov 10, 2003: Otsuka’s Tolvaptan Shows Decreased Fluid Retention In Hospitalized Patients With Worsening Congestive Heart Failure Data on Novel Phase III Agent Presented at Late Breaking Clinical Trials Session During American Heart Association’s Scientific Sessions 2003
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Hyponatremia, H1 2012
Products under Development for Hyponatremia – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Cornerstone Therapeutics Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Hyponatremia Therapeutics – Drug Profile Updates
Hyponatremia Therapeutics – Discontinued Products
Hyponatremia Therapeutics – Dormant Products
List of Figures
Number of Products under Development for Hyponatremia, H1 2012
Products under Development for Hyponatremia – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
